TLR3
Toll-like receptor 3
As of the edition of 20 October 2026, TLR3 (toll-like receptor 3, UniProt O15455) has 2 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O15455
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 20
- Disease areas
- Cancer; Urinary and reproductive; Infections; Digestive system; Immune system; Eye; Hormones; Skin and connective tissue
- Registered trials of its drugs
- 31
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rintatolimod | Stopped | Phase 3 | none listed |
| Bevasiranib | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| AIM ImmunoTech | Route A |
| OPKO Health | Route A |
The other 1 company at TLR3
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at TLR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.